CCHT(SZ:000661) Ge Long Hui A P P·2025-10-21 13:19Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received the Acceptance Notice from the National Medical Products Administration for the clinical trial application of GenSci142 capsules, which are developed to target Gardnerella bacteria [1] Group 1 - Jinsai Pharmaceutical's GenSci142 capsules are a recombinant lytic enzyme that can directly disrupt bacterial cell walls, leading to rapid lysis and death of the bacteria [1] - The drug offers several core advantages over traditional medications, including rapid onset of action, precise bactericidal activity, efficient biofilm clearance, low risk of resistance, and safety in local application [1]